[R] R vs. Splus in Pharma/Devices Industry

[John Kane]

--- Douglas Bates <bates at stat.wisc.edu> wrote:

> On 6/15/07, Nicholas Lewin-Koh <nikko at hailmail.net>
> wrote:
> > Hi,
> > I just saw this thread. This issue, and the larger
> scale issue of open
> > source in industry
> > is being addressed. One has to realize that the
> behemoth that is the
> > clinical aperatus
> > of the pharma industry is very conservative and
> very slow to change. In
> > many cases
> > switching to R would meean changing a great many
> processes all based on
> > legacy code. One
> > of the big issues is that the industry demands
> consistency not
> > necessarily correctness.
> >
> > All that said there are a great many areas where R
> could be used that
> > would not impact
> > regulatory submission, data security etc. Many in
> pharma are quietly
> > working on this,
> > but steps are small and incremental. Development
> takes time in industry
> > because of the amount of
> > documentation necessary. All this impacts the
> "free" nature of R and
> > cost and risk (From the industries
> > perspective) need to be justified.
> 
> > Probably when the statistical community is using Z
> big pharma will be
> > ready to use
> > R. %P
> 
> I think you mean A, not Z.  First there was S, then
> there was R.

We're regressing !!!!